Welcome to Mælandsmo's Group
The research group is studying biological and therapeutic aspects of the metastatic process, the principle cause of death in cancer patients.
Our goal is to better understand the underlying biological mechanisms causing treatment resistance,invasion and re-growth of cancer cells in other organs, and use this information for identification of potential target molecules or biomarkers that can be utilized in cancer therapy.
We are doing so by:
1) studying molecular determinants and testing novel therapies in preclinical model systems in vivo and in vitro, and by
2) utilizing patient material collected in clinical intervention studies or from prospectively collected biobanks.
The group is partner in the NANOCAN project (Biodegradable Nanoparticles in Cancer Diagnosis and Therapy, headed by Prof Kirsten Sandvig, Department of Molecular Cell Biology, ICR)
We are also partner in the Oslo Breast Cancer Research Consortium (OSBREAC) and in the Regional Network for Breast Cancer Research. In 2013-2016 we participated in the K.G. Jebsen Centre for Breast Cancer Research (headed by Prof. Anne-Lise Børresen-Dale), and in the Cancer Stem Cell Centre for Research Based (CAST SFI) in the period 2010-2014.
Mælandsmo and Børresen-Dale are the Principle Investigators of the MetAction project where we together with clinical collaborators are responsible for the first clinical trial in Norway offering targeted treatment based on identification of actionable targets in metastatic biopsies. Metaction
Click on the sections below to read more:
The Norwegian Radium Hospital, Montebello, Box 4953 Nydalen, 0424 Oslo, Norway
Phone: +47 22 78 18 79(Mælandsmo) Fax: +47 22 78 17 95
Growth coordination during development
Mar 27, 2017
Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology
Mar 15, 2017
Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research
Mar 7, 2017
Metastasis: biology and therapy group
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nat Rev Cancer, 17 (4), 254-268
Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Breast Cancer Res Treat, 162 (1), 127-137